The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.
The study will assess the safety and anti-tumor activity of the IL-7 agent and the checkpoint inhibitor combination for patients with PD-L1-expressing NSCLC.
The NCCN's research program will put out a request for proposals early next year for studies to investigate neratinib in various molecularly defined cancers.
